Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT800 On-demand Treatment in Hemophilia A
NCT02921945Phase 3Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omfiloctocog alfa in hemophilia A, sponsored by Sinocelltech Group Limited. Primary endpoint: Incremental Recovery (K-value). Status: unknown.
02
Drugs
omfiloctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02921945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921945.